Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01365507 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
NCT01365507 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 276 participants.
The verdict
NCT01365507, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
Study Summary
This trial is conducted in Asia and North America. The aim of this trial is to compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily in insulin-naïve subjects with type 2 diabetes mellitus when using two different titration algorithms (dose individually adjusted) as add-on to subject's ongoing treatment with metformin.
Interventions
- DRUG insulin degludec/insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01365507
The ClinicalTrials.gov registry entry for NCT01365507 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which insulin degludec/insulin aspart is the first listed.
NCT01365507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01365507 about?
NCT01365507 is a clinical study titled "Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens". This trial is conducted in Asia and North America. The aim of this trial is to compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily in insulin-naïve subjects with type 2 diabetes mellitus when using two different titration algorithms (dose individually adjusted) as...
What is the current status of trial NCT01365507?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2011-06. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01365507?
The interventions under investigation include: insulin degludec/insulin aspart (DRUG).
Who is sponsoring clinical trial NCT01365507?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.